GlaxoSmithKline Pharmaceuticals reports a five-fold jump in net profit for the third quarter ending December 31, 2024, ...

GlaxoSmithKline Pharmaceuticals reported a significant increase in net profit to Rs 229 crore for the third quarter ending ...

In the vaccines segment, GSK maintained its leadership in the self-pay private market for Paediatric vaccines, the company ...

While vaccine sales dropped, GSK raised its revenue guidance for 2031 with speciality medicines expected to drive that growth ...

GSK launched a 2 billion pounds ($2.5 billion) share buyback on Wednesday and lifted its long-term sales target to nearly $50 ...

GlaxoSmithKline Pharmaceuticals Ltd reported an 18% revenue increase to ₹946 crore for Q3 ended December 31, 2024, with a ...

GSK (LSE: GSK) has reported a 7% increase in full-year revenue for 2024, reaching £31.4 billion ($39.3 billion), slightly ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.

The annual per capita pharmaceutical sales are less than US$32. Most of this spent is out of the pocket. By providing a big portfolio of 140 products with a relative low price, GSK is winning the ...

Mark Hartley weighs up the growing potential in GSK as its share price makes rare gains following a promising set of results.